

leukaemia¹⁶) were not predicted by animal studies using similar doses of vector.

One set of questions on toxicology related to gene transfer arises because most studies in humans—as with many other trials of hazardous agents—enrol participants with advanced illness. Such participants are likely to misinterpret the purpose of the trial as providing therapy rather than producing generalisable knowledge.¹⁷ Enrolment in studies on the safety of gene transfer is therefore susceptible to being based on “misinformed” consent. Also, participants who perceive a trial as providing therapy may be less willing to comply with intrusive procedures (for example, long term follow up and autopsy) that are aimed at testing safety. By policing consent procedures for language that promotes misconceptions about therapy, investigators may encourage participants to cooperate with a trial’s toxicological aspects.¹⁸

Premarketing studies of drugs often have insufficient power to expose rare adverse events¹⁹; the collection of toxicity data is further hampered because gene transfer trials generally enrol participants with severe illness. For instance, attributing causes for adverse events is confounded by underlying medical conditions. Moreover, such populations are unlikely to survive and experience theoretically predicted latent adverse events. Therefore, many risks will only be characterised once gene transfer extends to populations with less severe medical conditions; patients and the public (rather than trial participants) will likely bear many of the risks involved in characterising latent toxicity.

Owing to the uncertainties and inexperience surrounding risks from gene transfer, systems may need to be established for postmarketing surveillance (for example, registries) and the long term follow up of trial participants. In the United States, such long term follow up is not mandatory, and anecdotal evidence indicates that it is not widely practised.¹⁸ In contrast, the United Kingdom²⁰ and Australia (www7.health.gov.au/nhmrc/research/gtrap.htm) track the medical records of recipients of gene transfer. Follow up and post-marketing surveillance are potentially costly, can medicalise people’s lives, and infringe on their privacy. Nevertheless, spontaneous reporting of adverse events is unreliable for detecting latent adverse events,¹⁹ and more active measures may be necessary to protect the public, and patients and their descendants, should gene transfer expand to milder medical conditions.

Although recent trials confirm the feasibility of gene therapy, they also highlight that its risks are poorly understood. The task for researchers in gene transfer will be to characterise these risks while attending to the complex ethical challenges of conducting gene transfer studies in humans.

JK is the sole contributor to this paper.

Funding: Canadian Institutes of Health Research.

Competing interests: None declared.

- 1 Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat Genet* 2000;24:257-61.
- 2 Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. *N Engl J Med* 2002;346:1185-93.
- 3 Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. *Science* 2002;296:2410-3.
- 4 Marshall E. Gene therapy. Viral vectors still pack surprises. *Science* 2001;294:1640.

- 5 Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 2003;302:415-9.
- 6 Williams D. Clarity and risk: the challenges of the new technologies. *Med Device Technol* 2001;12:12-4.
- 7 Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. *Blood* 2003;101:2099-14.
- 8 Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. *Mol Genet Metab* 2003;80:148-58.
- 9 Dettweiler U, Simon P. Points to consider for ethics committees in human gene therapy trials. *Bioethics* 2001;15:491-500.
- 10 Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? *JAMA* 2000;283:2701-11.
- 11 Kimmelman J. Protection at the cutting edge: the case for central review of human gene transfer research. *CMAJ* 2003;169:781-2.
- 12 Orkin SH, Motulsky AG. Report of the National Institutes of Health ad hoc committee. *Report and recommendations of the panel to assess the NIH investment in research on gene therapy*. Bethesda, MD: National Institutes of Health, 7 Dec 1995. Available at www4.od.nih.gov/oba/rac/panelrep.htm
- 13 King NMP. Defining and describing benefit appropriately in clinical trials. *J Law Med Ethics* 2000;28:332-43.
- 14 Kohn DB, Sadelain M, Glorioso JC. The occurrence of leukemia following gene therapy. *Nat Rev Cancer* 2003;3:477-88.
- 15 Welin S. Starting clinical trials of xenotransplantation—reflections on the ethics of the early phase. *J Med Ethics* 2000;26:231-6.
- 16 Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. *Mol Ther* 2003;8:180-7.
- 17 Lidz CW, Appelbaum PS. The therapeutic misconception: problems and solutions. *Med Care* 2002;40:V55-63.
- 18 King NMP. Accident and desire: inadvertent germline effects in clinical research. *Hastings Cent Rep* 2003;33:23-30.
- 19 Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions. *JAMA* 1999;281:824-9.
- 20 Nevin NC, Spink J. Gene therapy advisory committee: long-term monitoring of patients participating in gene therapy: health departments of the United Kingdom. *Hum Gene Ther* 2000;11:1253-5. (Accepted 9 November 2004)

Corrections and clarifications

The next small step

The author of this article in our Christmas issue, Kevin Fong, has notified us that his email address is missing its first full stop (*BMJ* 2004;329:1441-4, 18-25 Dec). His correct address is k.fong@ucl.ac.uk.

Monitoring global health: time for new solutions

The authors of this Education and Debate article (who argued that a new global health monitoring organisation is needed to replace the World Health Organization) would like to clarify for readers that they have all had recent links with WHO (*BMJ* 2004;329:1096-100, 6 Nov). Christopher J L Murray worked for WHO until 15 September 2003, Alan D Lopez worked for the organisation until 1 January 2002, and Suwit Wibulpolprasert has served on a number of advisory committees to WHO.

If the honey doesn't get you, the bees will

A lapse in concentration by Harvey Marcovitch, the author of the summaries on the BMJ Family Highlights page, led to the inadvertent omission of the word haemorrhagic in this summary on the BMJ Family Highlights page (*BMJ* 2004;329:1368, 11 Dec). The third sentence should have read: “Computed tomography of the head and magnetic resonance imaging of the brain showed a large right temporo-occipital haemorrhagic infarct.”

Cadavers as teachers: the dissecting room experience in Thailand

In this article by Andreas Winkelmann and Fritz H Güldner in our Christmas issue, we forgot to carry out the authors’ wishes that we acknowledge Professor G H Schumacher from Rostock, Germany, as the provider of the photograph (*BMJ* 2004;329:1455-7, 18-25 Dec).